Hamza Hashmi, Myeloma and Cellular Therapy Physician at Memorial Sloan Kettering Cancer Centre, shared a post on X, by Robert Z Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, about a recent article, adding:
“Not all MRD resurgent pts are the same; some have ‘immune’ MRD negativity (naive PB T cell phenotype) that predicts long-term disease control without the need for change of therapy. Excellent work by Ross Firestone and Memorial Sloan Kettering Cancer Center.”
Quoting Robert Z Orlowski‘s post:
“Myeloma Paper of the Day: Immune-MRD status informs tumor-MRD outcome prognostication in myeloma patients on Len maintenance; T cell profiles enriched with activated cytotoxic effectors predict early relapse and quiescent/naïve T-cells predicting remission.”
Title: Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance
Authors: Ross S. Firestone, Anish K. Simhal, Devin McAvoy, Eric M. Jurgens, Juan-Jose Garcés, David Nemirovsky, Andriy Derkach, Kylee H. Maclachlan, Malin Hultcrantz, Sham Mailankody, Urvi A. Shah, Carlyn R. Tan, Neha Korde, Hani Hassoun, Sridevi Rajeeve, Hamza Hashmi, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Benjamin T. Diamond, Francesco Maura, Kinga Hosszu, David J. Chung, Ola Landgren, Saad Z. Usmani, Alexander M. Lesokhin
Read the Full Article in the National Library of Medicine.
More posts featuring Hamza Hashmi on OncoDaily.
